Advertisement

Zusammenfassung

Der Begriff der Demenz umfasst die erworbene Beeinträchtigung höherer Hirnfunktionen, d.h.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Ala TA, Yang KH, Sung JH, Frey WH (1999) Clinical parkinsonism in dementia patients with substantia nigra Lewy bodies. J Neural Transm 106/1:47–57PubMedCrossRefGoogle Scholar
  2. 2.
    Baas H, Deuschl G, Oertel W, Poewe W (1996) Medikamentöse Therapie der Parkinson- Krankheit. Sonderdruck Deutsches Ärzteblatt, 93. Jahrgang, Heft 39, A:S 2470–2477, B:S 1941–1948, C:S 1753–1760Google Scholar
  3. 3.
    Berger M, Stieglitz R-D (1999) Psychiatrie und Psychotherapie. Urban & Schwarzenberg, München Wien BaltimoreGoogle Scholar
  4. 4.
    Biggis CA, Boyd JL, Harrop FM, Madeley P, Mindham RHS, Randall JI, Spokes EGS (1992) A controlled, longitudinal study of dementia in Parkinson’s disease. J Neurol Neurosurg Psychiatry 55:566–571CrossRefGoogle Scholar
  5. 5.
    Bohlken J (1999) Psychotherapeutische Strategien bei Demenz. Neurotransmitter Münch med Wschr, Sonderheft 1/99:16–21Google Scholar
  6. 6.
    Boller F, Mizutani T, Roessmann U, Gambetti P (1980) Parkinson Disease, Dementia, and Alzheimer Disease: Clinicopathological Correlations. Ann Neurol 7/4:329–335PubMedCrossRefGoogle Scholar
  7. 7.
    Bornkessel B (1998) Diagnostik und Behandlung der Alzheimer-Krankheit. Arzneimitteltherapie 16/4:115–117Google Scholar
  8. 8.
    Borromei A (1989) Adjuvant therapy for Parkinson’s disease. Preliminary data of a mul- ticentre study with nicergoline. Funct Neurol 4:63–67Google Scholar
  9. 9.
    Burke WJ, Ranno AE, Roccaforte WH, Wengel SP, Bayer BL, Willcockson NK (1993) L-Deprenyl in the Treatment of Mild Dementia of the Alzheimer Type: Preliminary Re- sults. JAGS 41/4:367–370Google Scholar
  10. 10.
    Caplan L (1995) Binswangens disease - revised. Neurology 45:626–633PubMedGoogle Scholar
  11. 11.
    Carl G (1999) Sind Antidementiva noch verordnungsfähig? Neurotransmitter Münch med Wschr, Sonderheft 1/99:6–10Google Scholar
  12. 12.
    Ditzler K (1991) Wirksamkeit und Verträglichkeit von Memantine bei Patienten mit dementieilen Syndrom. Eine doppelblinde, Placebo-kontrollierte Studie. Sonderdruck Arzneim Forsch/Drug Res 41(II) 8:773–780Google Scholar
  13. 13.
    Doraiswamy PM (1996) Current Cholinergic Therapy for Symptoms of Alzheimer’s Disease. Primary Psychiatry 3/11:3–11Google Scholar
  14. 14.
    Fischer C (1982) Lacunar strokes and infarcts: a review. Neurology 32:871–876Google Scholar
  15. 15.
    Fratiglioni L, Viitanen M, von Strauss E, Tontodonati V, Herlitz A, Winblad B (1997) Very old women at highest risk of dementia and Alzheimers sdisease: Incidence data from the Kungsholmen Project, Stockholm. Neurology 48:132–138PubMedGoogle Scholar
  16. 16.
    Glatt SL, Hubble JP, Lyons K, Paolo A, Troster AI, Hassanein RE, Koller WC (1996) Risk factors for dementia in Parkinson’s disease: effect of education. Neuroepidemiology 15/1:20–25PubMedCrossRefGoogle Scholar
  17. 17.
    Grobe-Einsler R, Traber J (1992) Clinical Results with Nimodipine in Alzheimer Disease. Clin Neuropharm Suppl 1, 15:416–417CrossRefGoogle Scholar
  18. 18.
    Hampel H, Padberg F, Möller H-J (1998) Donepezil in der Pharmakotherapie der Alzheimer Krankheit. Psychopharmakotherapie Sonderdruck 5/2:54–61Google Scholar
  19. 19.
    Haupt M (1999) Demenz: Angehörigenbetreuung durch den Hausarzt ist essentiell. Geriatrie Praxis 2:28–33Google Scholar
  20. 20.
    Hennerici M (1997) Vaskuläre Demenzen. In: Förstl H (Hrsg) Lehrbuch der Gerontopsy- chiatrie. Enke Verlag, Stuttgart, S 309–330Google Scholar
  21. 21.
    Hermann WM, Kern U (1987) Nootropika: Wirkungen und Wirksamkeit. Nervenarzt 58:358–364Google Scholar
  22. 22.
    Herrschaft H (1992) Nicergolin. Neuro-Psychopharmaka Bd. 5. In: Riederer, Laux, Pöldinger (Hrsg). Springer-Verlag, Wien, pp 313–323Google Scholar
  23. 23.
    Hughes TA (2000) A 10-year study of the incidence of and factors predicting dementia in Parkinson disease. Neurology 54:1596–1602PubMedGoogle Scholar
  24. 24.
    Hutchinson M, Fazzini (1996) Cholinesterase inhibition in Parkinson’s disease. J Neurol Neurosurg Psychiatry 6–1:324–325CrossRefGoogle Scholar
  25. 25.
    Ihl R, Kretschmar C (1997) Zur Nootropikabewertung für die Praxis. Nervenarzt 11/68:853–861CrossRefGoogle Scholar
  26. 26.
    Kanowski S (1991) Klinischer Wirksamkeitsnachweis bei Nootropika. Münch med Wschr Suppl. 1, 133:5–8Google Scholar
  27. 27.
    Kawas C, Resnick S, Morrison A, Brookmeyer R, Corrada M, Zondermann A, Bacal C, Donnell Lingle D, Metter E (1997) A prospective study of estrogen replacement therapy and the risk of developing Alzheimers disease: The Baltimore Longitunal Study of Aging. Neurology 48:1517–1521PubMedGoogle Scholar
  28. 28.
    Knopman D, Schneider L, Davis K, Talwalker S, Smith F, Hoover T, Gracon S (1996) Long-term tacrine (Cognex) treatment: Effects on nursing home placement and mortality. Neurology 47:166–177PubMedGoogle Scholar
  29. 29.
    Kogan E, Henneberg AE (2000) Parkinson-Plus-Dementia-Syndrome - Successful Treatment by Rivastigmine. Reprinted from: 5th Congress of the European Society for Clinical Neuropharmacology. Opatija (Croatia), May 17–21Google Scholar
  30. 30.
    Kurz A (1998) Alzheimer-Krankheit: Aktueller Stand der Pharmakotherapie. Geriatrie Praxis 4/98:18–23Google Scholar
  31. 31.
    Kurz A (1999) Handbuch der Betreuung und Pflege von Alzheimer-Patienten. Thieme, StuttgartGoogle Scholar
  32. 32.
    Lieberman A (1998) Managing the neuropsychiatric symptoms of Parkinson’s disease. Neurology Suppl 6, 50:33–38Google Scholar
  33. 33.
    Litvan I (1998) Parkinsonism-Dementia Syndromes. In: Jankovic J, Tolosa E (Hrsg.) Parkinson’s Disease and Movement Disorders. Lippincott Williams 8c Wilkins, Baltimore, S 819–836Google Scholar
  34. 34.
    McKeith IG, Grace JB, Walker Z, Byrne EJ, Wilkinson D, Stevens T, Perry EK (2000) Rivastigmine in the treatment of dementia with Lewy Bodies: preliminary findings from an open trial. J Geriat Psychiatry 15:387–392CrossRefGoogle Scholar
  35. 35.
    Müller WE (1988) Nootropika. Therapie der Demenz zwischen Anspruch und Wirklichkeit. Münch med Wschr 13/31–32:575–579Google Scholar
  36. 36.
    Naimark D, Jackson E, Rockwell E, Jeste DV (1996) Psychotic symptoms in Parkinson’s disease patients with dementia. J Am Geriatr Soc 44/3:296–299PubMedGoogle Scholar
  37. 37.
    Plendl H (1999) Die Pharmakotherapie der Demenz. Neurotransmitter Münch med Wschr, Sonderheft 1/99:11–15Google Scholar
  38. 38.
    Poewe W, Schelosky L (1994) Die Neuropsychologie der Parkinson-Erkrankung. In: Huffmann G, Braune H-J, Henn K-H (Hrsg) Extrapyramidal-motorische Erkrankungen. Einhorn-Presse Verlag GmbH, Reinbek, S 242–246Google Scholar
  39. 39.
    Pondal M, Del Ser T, Bermejo F (1996) Anticholinergic therapy and dementia in patients with Parkinson’s disease. J Neurol 243/7:543–546PubMedCrossRefGoogle Scholar
  40. 40.
    Rajput AH, Rozdilsky B, Rajput A (1993) Alzheimer’s Disease and Idiopathic Parkinson’s Disease Coexistence. J Geriatr Psychiatry Neurol 6:170–176PubMedGoogle Scholar
  41. 41.
    Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT (1998) A 24-week, doubleblind, placebo-controlled trial of donepezil in patients with Alzheimers disease. Neuro- logy 50:136–145Google Scholar
  42. 42.
    Rösler M, Retz-Junginger P, Retz W (1998) Alzheimer Demenz und Exelon. Thieme, StuttgartGoogle Scholar
  43. 43.
    Saletu B, Paulus E, Linzmayer L, Anderer P, Semlitsch HV, Grünberger J, Wicke L, Neuhold A, Podreka I (1995) Nicergolin bei seniler Demenz vom Alzheimer Typ und Multi- infarktdemenz: Eine doppelblinde, placebokontrollierte, klinische und EEG/EP-Mapping Studie. Psychopharmacology 117:385–395PubMedCrossRefGoogle Scholar
  44. 44.
    Sano M, Stern Y, Marder K, Mayeux R (1990) A Controlled Trial of Piracetam in Intel- lectually Impaired Patients with Parkinson’s Disease. Mov Disord 5/3:230–234PubMedCrossRefGoogle Scholar
  45. 45.
    Schneider LS, Farlow MR, Henderson VW, Pogoda JM (1996) Effects of estrogen repla- cement therapy on response to tacrine in patients with Alzheimer’s disease. Neurology 46:1580–1584PubMedGoogle Scholar
  46. 46.
    Shea C, MacKnight Ch, Rockwood K (1998) Donepezil for Treatment of Dementia with Lewy Bodies: A Case Series of Nine Patients. International Psychogeriatrics 10/3: 229–238PubMedCrossRefGoogle Scholar
  47. 47.
    Stoppe G, Brandt CA, Staedt JH (1999) Behavioural problems associated with dementia: the role of newer antipsychotics. Drugs Aging 14/1:41–54PubMedCrossRefGoogle Scholar
  48. 48.
    Waters CH (1997) Managing the late complications of Parkinsons disease. Neurology Suppl 1, 49:49–57Google Scholar
  49. 49.
    Watkins PB, Zimmermann HJ, Knapp MJ, Gracon SI, Lewis KW (1994) Hepatotoxic Effects of Tacrine Administration in Patients With Alzheimer’s Disease. JAMA 271/13: 992–998PubMedCrossRefGoogle Scholar
  50. 50.
    Wenning GK, Pramstaller PP, Ransmayr G, Poewe W (1997) Atypische Parkinsonsyn- drome. Nervenarzt 68:102–115PubMedCrossRefGoogle Scholar
  51. 51.
    Workman RH, Orengo CA, Bakey AA, Molinari VA, Kunik ME (1997) The use of risperidone for psychosis and agitation in demented patients with Parkinson’s disease. J Neuropsychiatry Clin Neurosci 9/4:594–597PubMedGoogle Scholar

Copyright information

© Steinkopff Verlag, Darmstadt 2000

Authors and Affiliations

  • N. Kühnl

There are no affiliations available

Personalised recommendations